Targeted, oral agent Enzastaurin shows favorable results

The data presented were gathered from a multicenter Phase II study of enzastaurin as a second- or third-line treatment of NSCLC (ASCO Abstract #7543 ). The rationale for the study was based on en-zastaurins unique mechanism of action as a serine/threonine kinase inhibitor, which is believed to suppress signaling through the PKC- and PI3K/AKT pathways. Historically, over-expression and ac-tivity of PKC- and PI3K/AKT have been associated with poor prognosis and treatment resistance in NSCLC. The primary objective of the study was progression-free survival at six months. Secondary endpoints were safety and overall survival at 12 months.

These data in NSCLC shed new light on the potential versatility of this agent, said Richard Gaynor, M.D., vice president, cancer research and global oncology platform leader for Lilly. Our objective with enzastaurin is to continue investigating the efficacy and safety of this unique molecule in order to determine the diseases where enzastaurin could have the most positive impact on patients.

In the study, patients received 500 mg of oral enzastaurin, once daily, until disease progression or un-acceptable toxicity occurred. In the 54 patients enrolled, the median progression-free survival was 1.9 months (95% Confidence Interval: 1.7-1.9) and the progression-free survival rate at six months was 14% (95% CI: 4.4%-23.6%). The median overall survival was 9.9 months (95% CI: 6.5-14.6). The overall survival rate at 12 months was 46.3% (95% CI: 32.1%-60.5%). The most common toxicity was fatigue. Additional toxicities observed included ataxia (n=1), thromboembolism (n=1), anemia (n=1) and dizziness.

Based on the encouraging survival and tolerability data gathered thus far, further evaluation of en-zastaurin in NSCLC, as a single agent or in combination, is warranted, said chief investigator for the study, Gerold Bepler, M.D., Ph.D., chief of thoracic oncology at the H. Lee Moffitt Cancer Center and Research In

Contact: Neil Hochman
CPR Worldwide

Page: 1 2

Related medicine news :

1. Shark cartilage shows no benefit as a therapeutic agent for lung cancer
2. Studies suggest investigational agent reduces disease activity in MS
3. Novel anti-oxidant and anti-inflammatory agent shows effectiveness on key endpoints in trial
4. MRI contrast agent can detect heart attack in the making
5. Contrast agent puts new light on diagnosing breast cancer
6. New reagent delivers a chemical breakthrough at FSU
7. High-resolution imaging with contrast agent shows promise in osteoarthritis research
8. Study suggests anesthetic agent may have rapid antidepressant effects
9. Alzheimers medication shows promise in treating nerve agent and pesticide poisoning
10. Cranberries contain possible anti-caries/anti-plaque agents
11. New contrast agents may be on horizon for better medical imaging

Post Your Comments:

(Date:2/13/2019)... , ... February 13, 2019 , ... Diameter Health ... has been issued a Federal Information Security Management Act (FISMA) High General Support System ... validation of a secure environment is mandatory for the VA because of their work ...
(Date:2/13/2019)... ... February 13, 2019 , ... Castle announced today that it ... from existing investors Y Combinator , First Round and F-Prime ... Duo Security, René Bonvanie, CMO at Palo Alto Networks, and Olivier Pomel, CEO at ...
(Date:2/13/2019)... (PRWEB) , ... February 13, 2019 , ... ... eye care practice management organizations in the nation, announced a new addition to ... the first-ever stand-alone oculofacial center created within a multi-specialty ophthalmology practice. ...
(Date:2/13/2019)... ... February 13, 2019 , ... A Place at Home ... from Home Care Pulse. The Employer of Choice Award is granted only to the ... an independent satisfaction research firm for home care. A Place at Home is ranked ...
(Date:2/13/2019)... ... February 13, 2019 , ... Surgery that moves both jaws forward – ... obstructive sleep apnea (OSA), resulting in benefits that include improved breathing, daytime wakefulness and ... study. , MMA should be regarded as the preferred treatment for patients with moderate ...
Breaking Medicine News(10 mins):
(Date:2/13/2019)... (PRWEB) , ... February 13, 2019 , ... WellRyde, a ... trip sources on its platform. With the initial launch of Trip Market in early ... the platform. In a short span of time, Trip Market has contributed significantly to ...
(Date:2/13/2019)... ... February 13, 2019 , ... ClearCube® Technology, Inc. announces the ... in Orlando, Florida. The compact Thin Clients demonstrate their versatility in the healthcare, ... above respectively. , Powered by Intel® Celeron® N2807 dual-core processors with Intel® ...
(Date:2/13/2019)... ... 13, 2019 , ... Gastro Health, LLC (“Gastro Health”), announced ... P.A. DBA Gastroenterology Specialists (“Gastroenterology Specialists”), a leading physician group with more than ... the Central Florida market, after it acquired Central Florida Gastroenterology in August of ...
Breaking Medicine Technology:
Cached News: